Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Zymeworks BC Inc.ZYME · Entity 12038 | SVP & Chief Financial Officer | March 10, 2022 | March 11, 2022 |
| Zymeworks Inc.ZYME · Entity 4458 | SVP & Chief Financial Officer | January 05, 2024 | January 08, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Zymeworks BC Inc.
Report date March 10, 2022 · Filed March 11, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.00 · Expires 2032-03-09 | Direct | 125,000 |
Reported balance
After 2022-03-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-10 · Grant · Acquired 125,000 · Balance 125,000 F1: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date.
Zymeworks Inc.
Report date January 05, 2024 · Filed January 08, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,503 |
Ending reported balance
After 2024-01-08 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2024-01-05 · Exercise / conversion · Acquired 10,500 · Balance 12,497 F1: Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 5, 2023. Row 2 · 2024-01-05 · Sale · Disposed 4,563 · Balance 7,934 F2: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.55 to $10.845, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Row 3 · 2024-01-08 · Sale · Disposed 1,431 · Balance 6,503 F2: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.49 to $11.58, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 21,000 |
Reported balance
After 2024-01-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-01-05 · Exercise / conversion · Disposed 10,500 · Balance 21,000 F5: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F6: The RSUS were granted on January 5, 2023 and vest in three equal annual installments beginning on January 5, 2024. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 30,000 |
Reported balance
After 2024-01-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-01-05 · Grant · Acquired 30,000 · Balance 30,000 F5: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F8: The RSUs vest in three equal annual installments beginning on January 5, 2025. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.56 · Expires 2034-01-04 | Direct | 50,000 |
Reported balance
After 2024-01-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-01-05 · Grant · Acquired 50,000 · Balance 50,000 F7: Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 5, 2023.
F2: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.55 to $10.845, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.49 to $11.58, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F5: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
F6: The RSUS were granted on January 5, 2023 and vest in three equal annual installments beginning on January 5, 2024.
F7: Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date.
F8: The RSUs vest in three equal annual installments beginning on January 5, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 08, 2024 Filed Jan 8, 2024 18:14 UTC | Zymeworks Inc. ZYME · Entity 4458 | SaleCommon Stock | 1,431 | $11.22 | $16,049.52 |
DisclosureSEC source: 0000950170-24-003087 · ownership.xml · nonDerivative · entry 3 Astle Christopher · CIK 0001915257 · SVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,503 F2 · kind: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.49 to $11.58, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 05, 2024 Filed Jan 8, 2024 18:14 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantRestricted Stock Unit · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-003087 · ownership.xml · derivative · entry 6 Astle Christopher · CIK 0001915257 · SVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires not disclosed F5 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F8 · derivative.exercise_date: The RSUs vest in three equal annual installments beginning on January 5, 2025. F8 · derivative.expiration_date: The RSUs vest in three equal annual installments beginning on January 5, 2025. Read SEC document |
| January 05, 2024 Filed Jan 8, 2024 18:14 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $10.56 | $0.00 |
DisclosureSEC source: 0000950170-24-003087 · ownership.xml · derivative · entry 5 Astle Christopher · CIK 0001915257 · SVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-01-04 F7 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date. Read SEC document |
| January 05, 2024 Filed Jan 8, 2024 18:14 UTC | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionRestricted Stock Unit · Derivative | 10,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-003087 · ownership.xml · derivative · entry 4 Astle Christopher · CIK 0001915257 · SVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 10,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F6 · derivative.exercise_date: The RSUS were granted on January 5, 2023 and vest in three equal annual installments beginning on January 5, 2024. F6 · derivative.expiration_date: The RSUS were granted on January 5, 2023 and vest in three equal annual installments beginning on January 5, 2024. Read SEC document |
| January 05, 2024 Filed Jan 8, 2024 18:14 UTC | Zymeworks Inc. ZYME · Entity 4458 | SaleCommon Stock | 4,563 | $10.65 | $48,605.99 |
DisclosureSEC source: 0000950170-24-003087 · ownership.xml · nonDerivative · entry 2 Astle Christopher · CIK 0001915257 · SVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,934 F2 · kind: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.55 to $10.845, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 05, 2024 Filed Jan 8, 2024 18:14 UTC | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionCommon Stock | 10,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-003087 · ownership.xml · nonDerivative · entry 1 Astle Christopher · CIK 0001915257 · SVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,497 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 5, 2023. Read SEC document |
| December 11, 2023 Filed Dec 11, 2023 20:00 UTC | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionRestricted Stock Unit · Derivative | 1,550 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-069496 · ownership.xml · derivative · entry 3 Astle Christopher · CIK 0001915257 · SVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,550 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F5 · derivative.exercise_date: The RSUs were granted on December 10, 2021 and vested in two equal annual instalments (on December 12, 2022 and December 11, 2023). F5 · derivative.expiration_date: The RSUs were granted on December 10, 2021 and vested in two equal annual instalments (on December 12, 2022 and December 11, 2023). Read SEC document |
| December 11, 2023 Filed Dec 11, 2023 20:00 UTC | Zymeworks Inc. ZYME · Entity 4458 | SaleCommon Stock | 886 | $9.13 | $8,089.27 |
DisclosureSEC source: 0000950170-23-069496 · ownership.xml · nonDerivative · entry 2 Astle Christopher · CIK 0001915257 · SVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,997 F2 · kind: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.11 to $9.16, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 11, 2023 Filed Dec 11, 2023 20:00 UTC | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionCommon Stock | 1,550 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-069496 · ownership.xml · nonDerivative · entry 1 Astle Christopher · CIK 0001915257 · SVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,883 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares of common stock issued upon vesting of one half of the restricted stock units ("RSUs") granted on December 10, 2021. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 20:00 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantRestricted Stock Unit · Derivative | 31,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-001218 · doc4.xml · derivative · entry 2 Astle Christopher · CIK 0001915257 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,500 Underlying: Common Stock · 31,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs vest in three equal annual installments beginning on January 5, 2024. F3 · derivative.expiration_date: The RSUs vest in three equal annual installments beginning on January 5, 2024. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 20:00 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantStock Option (Right to Buy) · Derivative | 47,000 | $0.00 Strike: $8.00 | $0.00 |
DisclosureSEC source: 0000899243-23-001218 · doc4.xml · derivative · entry 1 Astle Christopher · CIK 0001915257 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,000 Underlying: Common Stock · 47,000 shares Expires 2033-01-04 F1 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 20:00 UTC | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionRestricted Stock Unit · Derivative | 1,550 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-038516 · doc4.xml · derivative · entry 3 Astle Christopher · CIK 0001915257 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,550 Underlying: Common Shares · 1,550 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F5 · derivative.exercise_date: The RSUs were granted on December 10, 2021 and vest in two equal annual instalments beginning on December 12, 2022. F5 · derivative.expiration_date: The RSUs were granted on December 10, 2021 and vest in two equal annual instalments beginning on December 12, 2022. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 20:00 UTC | Zymeworks Inc. ZYME · Entity 4458 | SaleCommon Stock | 887 | $6.01 | $5,330.87 |
DisclosureSEC source: 0000899243-22-038516 · doc4.xml · nonDerivative · entry 2 Astle Christopher · CIK 0001915257 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,333 F2 · kind: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs. Pursuant to the terms of the applicable RSU grant agreement (the "Grant Agreement"), effective on the grant date of the RSUs, the Reporting Person adopted a 10b5-1 plan pursuant to which the Reporting Person elected to sell shares to cover tax withholding obligations and other applicable fees in accordance with the terms of the Grant Agreement. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.99 to $6.035, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 20:00 UTC | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionCommon Stock | 1,550 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-038516 · doc4.xml · nonDerivative · entry 1 Astle Christopher · CIK 0001915257 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock issued upon vesting of one half of the restricted stock units ("RSUs") granted on December 10, 2021. Read SEC document |
| December 12, 2022 Filed Dec 23, 2022 20:00 UTC Amendment | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionRestricted Stock Unit · Derivative | 1,550 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-039332 · doc4a.xml · derivative · entry 3 Astle Christopher · CIK 0001915257 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,550 Underlying: Common Shares · 1,550 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F5 · derivative.exercise_date: The RSUs were granted on December 10, 2021 and vest in two equal annual instalments beginning on December 12, 2022. F5 · derivative.expiration_date: The RSUs were granted on December 10, 2021 and vest in two equal annual instalments beginning on December 12, 2022. Read SEC document |
| December 12, 2022 Filed Dec 23, 2022 20:00 UTC Amendment | Zymeworks Inc. ZYME · Entity 4458 | SaleCommon Stock | 887 | $6.01 | $5,330.87 |
DisclosureSEC source: 0000899243-22-039332 · doc4a.xml · nonDerivative · entry 2 Astle Christopher · CIK 0001915257 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,333 F2 · kind: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs. Pursuant to the terms of the applicable RSU grant agreement (the "Grant Agreement"), effective on the grant date of the RSUs, the Reporting Person adopted a 10b5-1 plan pursuant to which the Reporting Person elected to sell shares to cover tax withholding obligations and other applicable fees in accordance with the terms of the Grant Agreement. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.99 to $6.035, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 12, 2022 Filed Dec 23, 2022 20:00 UTC Amendment | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionCommon Stock | 1,550 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-039332 · doc4a.xml · nonDerivative · entry 1 Astle Christopher · CIK 0001915257 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock issued upon vesting of one half of the restricted stock units ("RSUs") granted on December 10, 2021. Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 21:00 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0000899243-22-010796 · doc4.xml · derivative · entry 1 Astle Christopher · CIK 0001915257 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Shares · 125,000 shares Expires 2032-03-09 F1 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.